Filter Results
Clinical Studies
Results filtered:Study status:
Open
Open
-
PAXIS: A Randomized, Double-blind, Placebo-controlled, Dose-finding Phase 2 Study (Part 1)
followed By An Open-label Period (Part 2) To Assess The Efficacy And Safety Of Pacritinib In Patients With
VEXAS Syndrome
Rochester, Minn.,
Scottsdale/Phoenix, Ariz.
The purpose of this stduy is to evaluate the efficacy of two dose levels of pacritinib compared to placebo during the double-blind treatment period in patients with VEXAS (i.e., Vacuoles in myeloid progenitors, E1 ubiquitin-activating enzyme, X-linked, autoinflammatory manifestations, and somatic) syndrome.
.